Growth HormoneResearch
ACE-031
Also known as: ACE031
An activin receptor decoy that blocks myostatin and related ligands to promote significant muscle growth. Studied for muscular dystrophy.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~10–14 days
Typical Dose
Research dosing
Administration
Subcutaneous injection
Mechanism of Action
Soluble ActRIIB decoy receptor that sequesters myostatin, activin A, and GDF-11, removing multiple negative regulators of muscle mass.
Key Research Areas
musclemyostatinactivinmuscular dystrophy
Frequently Asked Questions
What is ACE-031?▾
An activin receptor decoy that blocks myostatin and related ligands to promote significant muscle growth. Studied for muscular dystrophy.
How does ACE-031 work?▾
Soluble ActRIIB decoy receptor that sequesters myostatin, activin A, and GDF-11, removing multiple negative regulators of muscle mass.
What is the recommended dosage for ACE-031?▾
The typical research dosage is Research dosing, administered via Subcutaneous injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of ACE-031?▾
The half-life of ACE-031 is approximately ~10–14 days. This affects dosing frequency and timing in research protocols.
Is ACE-031 FDA approved?▾
ACE-031 is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about ACE-031 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.